Healthcare

AstraZeneca: Mega-Cap Growth Stock Now Trading at a Lower Price

AstraZeneca,(LSE:AZN),, the largest company on the FTSE 100, stands out as an unconventional,growth stock,with ambitious plans to nearly double its sa...

Genedrive (AIM: GDR) Receives FDA Breakthrough Device Designation fo...

Genedrive plc (,AIM: GDR,), a leader in point-of-care pharmacogenetic testing, has announced the receipt of Breakthrough Device Designation from the U...

Scancell Holdings (AIM: SCLP) Strikes Exclusive Evaluation Deal with...

Scancell Holdings plc (,AIM: SCLP,), a pioneer in the realm of oncology immunotherapies, has made waves once again with a significant announcement. Th...

ANGLE plc (AIM: AGL) Announces £8.5 Million Fundraising

ANGLE plc (,AIM: AGL,), a global leader in liquid biopsy technology, has announced plans for a significant fundraising effort aimed at raising approxi...

Prescription for Profit: Investing in LON Healthcare Stocks for Heal...

The healthcare sector is a vital and ever-growing industry that offers significant investment opportunities. In this article, we will explore the worl...

Healthcare stocks to explore amidst education and health sectors str...

Highlights The country was again in crisis as thousands of healthcare and education professionals went on strike, increasing the already prevalent...

Stocks to watch as the UK invests in the fight against deadly diseas...

Over the course of 3 years, the UK is channelising funds worth £1 billion towards the Global Fund.

Which FTSE health-related stocks to check out right now?

Highlights:,The Rishi Sunak government will face its first acid test as they gear up for the Autumn budget.,The fiscal statement is all set to be rele...

AstraZeneca boosts earnings guidance while demand strengthens

AstraZeneca declared its YTD and Q3 2022 results on Thursday.

Key stocks to watch as new clinical trials in UK declines

• The fall in clinical trials poses a severe threat to the country’s status as a clinical research hub.

PM Truss urged to put billions into social care

In her campaign, the PM had pledged to spend £13 billion on social care.

Haleon IPO: GSK gets shareholders' nod; all you should know

Highlights:,GSK Plc on Wednesday received approval from the shareholders for the demerger of its consumer healthcare arm.,The new entity, called Haleo...

AZN, GSK, HIK: Pharma stocks to consider amid fears of poliovirus sp...

Highlights:,Several closely-related poliovirus samples were found in the North and East London sewage.,The detection indicates there's been some sprea...

GSK's spin-off Haleon to be listed on LSE: Should you hold stock?

Pharma giant GSK plc (LON: GSK), which was previously known as GlaxoSmithKline plc, had in February announced that it would demerge its consumer healt...

Should you go for GlaxoSmithKline (GSK) share after solid Q1 results...

Highlights GlaxoSmithKline Plc announced its Q1 2022 results on Wednesday and surpassed expectations with a turnover of £9.8 billion. The...

AstraZeneca vs GlaxoSmithKline: Pharma stocks to keep an eye on

Leading British pharmaceutical company GlaxoSmithKline plc (LON: GSK) has been in the limelight lately after securing triumph for its drug with US reg...

Is OKYO Pharma (LON: OKYO) going for a Nasdaq listing?

Highlights OKYO Pharma is aiming to get its ADSs listed on Nasdaq and has submitted a registration statement with the US SEC for the same. The exc...

GlaxoSmithKline (LON: GSK) to start a new business era with Haleon

Highlights GlaxoSmithKline Plc has come one step closer to the proposed demerger of its consumer healthcare business by announcing the name of the...

AstraZeneca (AZN) predicts higher sales in 2022: Should you buy now?

Highlights  London’s FTSE100 index was in a buoyant mood on 10 February after it saw third day of gains in a row. The total revenues of...

GlaxoSmithKline (GSK) shares: Are they worth your attention?

British pharmaceutical giant GlaxoSmithKline Plc (LON: GSK) is back in the news after the company reported robust results for the year 2021 before the...